UEG Podcast

UEG Podcast

By UEG United European GastroenterologyScienceMedicineHealth & FitnessEducationLife Sciences
Download on the App Store

UEG Podcast episodes

  • Best of UEG Week 2026 - Nursing with Deepa Gandhi and Mary Phillips
    Clinician wellbeing, nurse-led research and long-term patient outcomes from Barcelona

    What did UEG Week 2026 offer nurses and allied health professionals? Mary Phillips, pancreatic dietitian and advanced clinical practitioner at a UK tertiary pancreatic centre, asks Deepa Gandhi, endoscopy nurse lead and President of ESGENA, for her highlights from Barcelona. Both keep returning to the human side of care: what complications mean for patients and clinicians, and how to train, support and keep specialist nursing staff.

    They discuss the second victim phenomenon, a nurse-led analysis of where time is lost in the endoscopy unit, and bile duct injury after laparoscopic cholecystectomy, a procedure patients tend to see as minor and are less prepared for when it goes wrong. Deepa's abstract highlights include a remote, postal small bowel capsule endoscopy service in Ireland, an activity-based assessment of endoscopy nursing workload and staffing, and advanced nurse practice in Austria. They also cover clinical educators in endoscopy, how nurses assess disease burden in Crohn's disease, long-term follow-up after acute pancreatitis, with its risk of diabetes and, after idiopathic pancreatitis, of cancer, and a multidisciplinary case of refeeding syndrome in anorexia nervosa. The conversation closes on burnout, and Deepa's call for more congress sessions on nurse wellbeing.

    Research and further reading

    Discussed in the episode (UEG Week 2026 presentations, recordings on Gutflix):

    • Second victim phenomenon – how can we prevent it. Fien Claessens. UEG Week 2026, ESGENA Opening Session.
    • Where do we lose time? A nurse-led analysis of workflow. Krisztina Tari. UEG Week 2026, ESGENA Opening Session.
    • Beyond borders: Managing a global nursing workforce – The impact of cultural diversity, beliefs, and training backgrounds on endoscopy services. Camille Dutronc, Deepa Gandhi, Joseph Garzia. UEG Week 2026, ESGENA Opening Session.
    • Life after bile duct injury. Vinay Kumar Kapoor. UEG Week 2026, "After the surgeon: A glimpse behind the survival curves".
    • Feasibility of implementing a remote small bowel capsule endoscopy service in an Irish tertiary referral centre. Lisa Keating. UEG Week 2026, nurse abstract NOP02.
    • Activity-based assessment of nursing workload in endoscopy: implications for optimal staffing. Riccardo Grande. UEG Week 2026, nurse abstract NOP06.
    • The implementation of advanced nursing practice in the field of endoscopy. Philipp Steegmüller. UEG Week 2026, nurse abstract NOP05.
    • The role of the clinical educator in endoscopy. Firenze Camille Mallari-Batac. UEG Week 2026, "Education of patients and staff".
    • Measuring disease burden in Crohn's disease: How nurses assess disease. Shellie Radford. UEG Week 2026, "Patient care: Requirements for special patient groups".
    • Life after liver transplant. Gonzalo Crespo. UEG Week 2026, "After the surgeon". Long-term outcomes after transplant.
    • Long-term consequences after pancreatic surgery. Mary Phillips. UEG Week 2026, "After the surgeon".
    • Mortality after acute pancreatitis: What are the hidden risks? Søren Schou Olesen. UEG Week 2026, "Life after acute pancreatitis: Risks, surveillance and management".
    • Abnormal glucose tolerance after acute pancreatitis: Who, when and how? Lucía Guilabert. UEG Week 2026, "Life after acute pancreatitis".
    • The transition from acute to chronic pancreatitis: Can we stop it? Bálint Erőss. UEG Week 2026, "Life after acute pancreatitis".
    • Beyond the field of view: Lessons from a challenging underwater ESD. Fabio Grilli. UEG Week 2026, ESGENA: Our most memorable cases. The water-immersion ESD talk with AI-simulated endoscopy.
    • Artificial intelligence and digital health in digestive diseases: From hype to implementation. Jakob Nikolas Kather. UEG Week 2026, Opening plenary.
    • Beyond calories: Managing complications and refeeding syndrome in clinical nutrition support. Chairs Monika Rau and Luca Havelda. UEG Week 2026, Postgraduate Teaching session. The multidisciplinary refeeding syndrome and anorexia nervosa case.

    Additional context (not discussed in the episode):

    • Medical error: the second victim. The doctor who makes the mistake needs help too. Wu AW. BMJ, 2000. The editorial that introduced the term.
    • In search of an international multidimensional action plan for second victim support: a narrative review. Seys D et al. BMC Health Services Research, 2023. Proposes five levels of support after patient safety incidents.
    • Long-term impact of iatrogenic bile duct injury. Schreuder AM et al. Digestive Surgery, 2020. Reviews long-term clinical and quality-of-life outcomes after bile duct injury.
    17 min
  • Best of UEG Week 2026 - Endoscopy with Giuseppe Vanella
    Simple questions, clinical impact: endoscopy highlights from UEG Week 2026

    On the final day of UEG Week 2026 in Barcelona, Egle Dieninyte talks to interventional EUS specialist Giuseppe Vanella (Milan) about the endoscopy research that stood out. Several of the strongest studies asked deliberately simple clinical questions.

    Key discussion points

    • The plenary trial on short-course antibiotics after adequate source control in cholangitis due to distal obstruction, and the selected population it applies to.
    • A Dutch randomised trial comparing primary percutaneous suprapapillary metal stenting with ERCP in malignant hilar strictures, and why the comparison is not like-for-like.
    • EUS-guided transmural drainage as a way to avoid crossing the tumour or papilla.
    • Two Italian trials of underwater versus gas-assisted ESD.
    • The “FOMO” of interventional EUS: training, volume and quality standards.
    • 16 min
    • New frontiers of PDAC screening and treatment with a basic scientist Pilar Acedo
      From RAS inhibitors to a KRAS vaccine: new hope in pancreatic cancer

      in this first part, Eglė talks with Dr Pilar Acedo Nuñez, a senior research fellow and junior principal investigator at UCL. Pilar co-leads the Pereira/Acedo Lab, which works on biomarkers for the early detection of pancreatic cancer and cholangiocarcinoma, and she is a former chair of the UEG Young Talent Group.

      Further reading

      • Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
      • First-in-human trial of mutant KRAS vaccine
      • 26 min
      • What's new in Rome V? Part 1 with Maura Corsetti
        New diagnoses, revised criteria and what changes in clinic

        Ten years after Rome IV, the Rome Foundation published Rome V in 2026, and with it a substantial revision of how disorders of gut–brain interaction (DGBI) are defined, diagnosed and managed. Pradeep Mundre is joined by Maura Corsetti, Associate Professor of Gastroenterology at the University of Nottingham, co-chair of the Rome V Bowel Disorders Committee and a member of the Rome Foundation Board of Directors, to work through what has actually changed, and what survives contact with a busy clinic..

        Further reading

        • Rome Foundation Brain–Gut Axis pocket card — the card Corsetti uses to explain the diagnosis; free download after registration.

        • Disorders of Gut–Brain Interaction and the Rome V Process — Drossman, Chang & Tack, Gastroenterology 2026;170:1083–98. The Rome V overview: nomenclature, the split between research and clinical criteria, and the rationale for each new diagnosis.

        • Bowel Disorders — Corsetti, Shin, Lacy et al., Gastroenterology 2026;170:1261–82. Corsetti's own Rome V chapter, containing the revised IBS criteria discussed at length.

        • Centrally Mediated Disorders of Gastrointestinal Pain — Fukudo, Aziz, Drossman et al., Gastroenterology 2026;170:1283–302. Where adult abdominal migraine (D2) and narcotic bowel syndrome sit in Rome V.

        • Anorectal Disorders — Rao, Bharucha, Carrington et al., Gastroenterology 2026;170:1318–46. The new anorectal sensory dysfunction disorders and their assessment and treatment.

        • Rome Foundation Clinical Diagnostic Criteria for Disorders of Gut-Brain Interaction — Gastroenterology 2022;162:675–9. The precursor to the Rome V clinical criteria, developed with primary care input.

        • The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders — Aziz, Palsson, Törnblom et al., Am J Gastroenterol 2018;113:86–96. The three-country population study underlying the overlap and quality-of-life data.

        • Rome V: a global framework for disorders of gut–brain interaction — Rome Foundation. Where to find the Rome V products and criteria.

        • 51 min
        • IBD in pregnancy with Mette Julsgaard - Part 2
          Active disease or a JAK inhibitor: which risk would you take?

          Asked to choose between a flare and a JAK inhibitor in the third trimester, Mette Julsgaard answers in two words: active disease.

          Part two picks up where aspirin for preeclampsia ended and moves to the situations that actually keep clinicians awake. Mette Julsgaard, Associate Professor at Aarhus University Hospital and a co-author of the 2025 global consensus statement on pregnancy in IBD, takes Pradeep Mundre through starting upadacitinib at 28 weeks when nothing else was left, why thiopurines should never be initiated in pregnancy even though they can be continued, and how to manage acute severe ulcerative colitis without letting surgery drift.

          Also here: why active perianal disease and a pouch push you towards caesarean section and why BCG waits six months but rotavirus does not.

          Part one covers fertility, preconception and the full drug run-through, be sure to listen to it, before you start with this episode.

          Further reading:

          • Rotavirus, the Canadian study
          • 21 min
          • IBD in pregnancy with Mette Julsgaard - Part 1
            Which IBD drugs to stop before conception, and which to keep

            One in three women with IBD believe every IBD drug is harmful in pregnancy. The cost of that belief shows up as flares, preterm births and babies born small for gestational age.

            Mette Julsgaard, Associate Professor at Aarhus University Hospital and Director of Denmark's National Centre for Preconception and Pregnancy in Autoimmune Diseases, was a co-author of the 2025 global consensus statement on pregnancy in IBD. With Pradeep Mundre she works through the period before conception: what active disease does to fertility in men and women, what to check at the preconception visit beyond disease activity, and why the stop list is short (JAK inhibitors, S1P receptor modulators and, in women, methotrexate).

            Then a drug by drug run through of pregnancy and breastfeeding, including why the biologics reach breast milk at under 1 % of maternal blood levels, as well as the recommendation for the use of aspirin for patients with IBD during pregnancy.

            Part two covers flares, surgery, delivery and vaccination and will be published on the 2nd of September 2026.

            Further reading:

            • Global consensus statement on the management of pregnancy in inflammatory bowel disease](https://doi.org/10.1136/gutjnl-2025-336402))
            • Fertility, the "large British study"
            • Ovarian reserve, the "two small studies". Study 1 Study 2](https://doi.org/10.1016/j.crohns.2012.03.003))
            • What predicts a flare in pregnancy
            • Methotrexate in men
            • Endoscopy in pregnancy, the AJG article Mette recommends
            • Calprotectin
            • PIANO registry
            • ECCO Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
            • Aspirin
            • 37 min
            • UEG Online Courses x UEG Podcast: Oesophageal Cancer
              A discussion on the current treatment of oesophageal cancer

              The literature said 41 to 46% of high-risk early oesophageal cancers already have nodal disease. Newer data from patients followed after endoscopic resection puts it nearer 16%, which means sending all of them to surgery operates on more than 80% for nothing.

              Recorded after the UEG online course on oesophageal cancer, three specialists work through the questions the guidelines have not settled. Roos Pouw on when strict endoscopic follow-up can replace oesophagectomy, and exactly what that follow-up schedule looks like. Ana-Maria Bucalau on why six biopsies no longer covers the biomarker panel, and what ESOPEC and MATTERHORN change about neoadjuvant choice. Jessie Elliott on Siewert type II surgery, and on ENSURE, which found intensive surveillance detects recurrence earlier without improving survival while increasing cancer worry.

              The SARONG surveillance trials are still recruiting and Jessie is open to hearing from interested centres. Full course at gutflix.eu.

              Further reading:

              1. ESGE tissue sampling guideline, Part 1 (biopsy numbers)

              2. PREFER registry, endoscopic follow-up after high-risk T1 resection
              3. ESOPEC, N Engl J Med 2025;392(4):323-335
              4. MATTERHORN, N Engl J Med 2025;393(3):217-230
              5. CARDIA protocol, BMC Cancer 2020;20(1):781
              6. ENSURE, Ann Surg 2023;277(5):e1035-e1044
              7. SARONG-II

              41 min
            • The Future of Faecal Microbiota Transplantation (FMT) with Maria Vehreschild (UEG Podcast rewind)

              UEG Podcast is on summer holiday and re-releases published episodes that we think deserve another listen. Enjoy!

              In this episode of the UEG Talks conversation between Maria Vehreschild and Pradeep Mundre, we delve into the complexities of the faecal microbiome and the role of faecal microbiota transplantation (FMT) in treating various diseases, particularly C. difficile infections and inflammatory bowel disease (IBD). The discussion covers the historical context of FMT, its mechanisms of action, current treatment guidelines, safety considerations, and the various delivery methods. The conversation also emphasises the need for further research and the importance of professional standards in FMT practices.

              32 min
            • Well-rounded care in functional disorders with Tim Vanuytsel (UEG Podcast rewind)

              UEG Podcast is on summer holiday and re-releases published episodes that we think deserve another listen. Enjoy!

              Functional gastrointestinal disorders, or disorder of gut-brain interaction, can be frightening to many GIs. How do I talk to the patient? What can I tell them if there is no improvement in their symptoms? How can I even explain to them what their diagnosis is, if I don’t even know it?

              To clear things up and provide clear points of action, our host Egle Dieninyte talked to Tim Vanuytsel from the University Hospital in Leuven, Belgium.

              The content of UEG Talks is for healthcare professionals and is purely educational. The views of the speakers are their own and do not necessarily reflect those of United European Gastroenterology. This podcast is not medical advice and should not replace clinical judgment. Always consult official guidelines and relevant experts before making patient care decisions.

              32 min

            About UEG Podcast

            From the publisher's feed

            Gastroenterology to-go! The UEG Podcast covers scientific, educational and professional development topics within the digestive health community. Listen as our two international experts (Egle…

            More shows like UEG Podcast

            Gut Podcast by BMJ Group

            Gut Podcast

            10 Listeners